Please assess the completion status of the following clinical trial:

Trial Title: Comparison of KADIAN 100 mg When Dosed With Alcohol Under Fasting and Fed Conditions Compared to Water

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adult male volunteers, 21 to 40 years of age.~* Subjects were non-smokers for at least 3 months or light smokers (less than 10 pack-years).~* Subjects with a history of moderate consumption of at least 7-21 units of alcohol per week or the alcohol equivalent (12 oz beer = 5 oz of 80-proof distilled spirits = 1 unit).~* Weighing at least 70 kg and within 20% of their ideal weights (table of Desirable Weights of Adults, Metropolitan Life Insurance Company, 1983).~* Medically healthy subjects with no clinically significant abnormalities in their laboratory profile and ECGs, as deemed by the Principal Investigator.~* Voluntarily consented to participate in the study.~Exclusion Criteria:~* History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease.~* In addition, history or presence of: alcoholism or drug abuse; asthma or other chronic respiratory illness; diabetes; gastrointestinal dysmotility, irritable bowel syndrome, chronic constipation or recent enteritis; hypersensitivity or idiosyncratic reaction to morphine or other opioids; hypersensitivity or idiosyncratic reaction to naltrexone, naloxone, or other opioids antagonists.~* History of no alcohol intake (alcohol-naive) or less than moderate alcohol intake.~* Subject with a history of alcohol intake exceeding the equivalence of 21 units/week or exceeding the average of 3 drinks per day.~* Subjects who had a surgery of the gastrointestinal tract (except appendectomy) which would interfere with absorption of the study drug.~* Subjects who received hepatic enzyme inducing drugs (e.g. Nizoral, Tagamet) within the previous three months.~* Subjects whose QTc interval was \>450 msec at screening and prior to dosing.~* Subjects whose sitting blood pressure was less than 110/45 mm Hg at screening or 100/45 mm Hg before dosing.~* Subjects who had been on a special diet (for whatever reason) during the 28 days prior to the first dose and throughout the study.~* Subjects who had made any significant donation or loss of blood within 56 days.~* Subjects who had made a plasma donation within 7 days prior to the study.~* Subjects with hemoglobin less than 12.0 g/dL.~* Subjects who had participated in another clinical trial within 28 days prior to the first dose.~* Subjects who had a positive urine test for drugs of abuse or alcohol.~* Subjects who had a positive test for, or had been treated for hepatitis B, hepatitis C or HIV.

- Gender: MALE
- Minimum Age: 21 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Regimen A (Type: EXPERIMENTAL): KADIAN Capsule + alcohol (under fasting conditions)
- Regimen B (Type: EXPERIMENTAL): KADIAN Capsule + alcohol (under fed conditions)
- Regimen C (Type: EXPERIMENTAL): KADIAN Capsule + water (under fasting conditions)
- Regimen D (Type: EXPERIMENTAL): Morphine sulfate IR oral solution + water (under fasting conditions)

Based on this trial design, predict the completion outcome and termination type (if applicable).